news
barchart

Represents the https://1investing.in/‘s profit divided by the outstanding shares of its common stock. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Plexus (PLXS) Q2 Earnings Top Estimates, Revenues Surge Y/Y – Nasdaq

Plexus (PLXS) Q2 Earnings Top Estimates, Revenues Surge Y/Y.

Posted: Thu, 27 Apr 2023 12:30:00 GMT [source]

Investors weren’t thrilled with the tech company’s fiscal second-quarter guidance. Live educational sessions using site features to explore today’s markets. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. Plexus shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. Plexus’ first-quarter fiscal 2023 results benefit from continued momentum across all segments and regions.

Plexus’ stock is owned by a number of institutional and retail investors. PLx Pharma’s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%).

Related News PLXS

Measures how much net income or profit is generated as a percentage of revenue.

marketbeat all access

Plexus uses resources or causes negative impacts mostly in categories “Scarce human capital”, “GHG emissions”, and “Societal stability & understanding among people”. The negative contribution in the “GHG emissions” impact category seems to be driven mostly by its “Military aircraft parts”, “Airplane components”, “Industrial robots”, and “Satellites” products. Plexus does not have a long track record of dividend growth. One share of PLXP stock can currently be purchased for approximately $0.01. By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

About PLXS

There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” PLXS shares. 2 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for PLx Pharma in the last year. The consensus among Wall Street research analysts is that investors should “hold” PLXP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLXP, but not buy additional shares or sell existing shares. Plexus Corp share price live 88.50, this page displays NASDAQ PLXS stock exchange data.

ratings

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The company said it expects revenue in the range of $1 billion to $1.05 billion for the fiscal third quarter. For the current quarter ending in June, Plexus expects its per-share earnings to range from $1.05 to $1.23. On a per-share basis, the Neenah, Wisconsin-based company said it had net income of $1.45. Sign-up to receive the latest news and ratings for Plexus and its competitors with MarketBeat’s FREE daily newsletter.

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.16 per share. Plexus Corp reported Q4 EPS of $1.78, $0.51 better than the analyst estimate of $1.27. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.01… Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.

Financial Calendars

Plexus Corp’s second-quarter performance is likely to benefit from new manufacturing contract wins and growing secular market trends. Plexus’ second-quarter fiscal 2023 results benefit from continued momentum across all segments and regions. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity.

11 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Pliant Therapeutics in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “buy” PLRX shares. 5 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Plexus in the last year.

  • Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
  • Since then, PLXS shares have decreased by 14.0% and is now trading at $88.50.
  • 11 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Pliant Therapeutics in the last twelve months.
  • The negative contribution in the “GHG emissions” impact category seems to be driven mostly by its “Military aircraft parts”, “Airplane components”, “Industrial robots”, and “Satellites” products.
  • Since then, PLRX shares have increased by 15.4% and is now trading at $22.31.

Raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager. The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023.

Plexus Corp Misses Q2 EPS by 4c

what is international trade theory has a short interest ratio (“days to cover”) of 4.6. 6.51% of the outstanding shares of Pliant Therapeutics have been sold short. The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Plexus Corp. (NASDAQ:PLXS) Shares Purchased by SG Americas … – MarketBeat

Plexus Corp. (NASDAQ:PLXS) Shares Purchased by SG Americas ….

Posted: Fri, 28 Apr 2023 09:37:47 GMT [source]

Value investors frequently look for companies that have low price/book ratios. According to 5 analysts, the average rating for PLXS stock is “Strong Buy.” The 12-month stock price forecast is $105.4, which is an increase of 19.10% from the latest price. Plexus’ stock was trading at $102.93 at the beginning of the year. Since then, PLXS shares have decreased by 14.0% and is now trading at $88.50. Pliant Therapeutics’ stock was trading at $19.33 on January 1st, 2023.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Goldman Sachs sees restructuring lowering earnings by 2 cents per share per quarter. All values as of most recently reported quarter unless otherwise noted.

Pliant Therapeutics does not have a long track record of dividend growth. Right-click on the chart to open the Interactive Chart menu. Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests.

In the past three months, Plexus insiders have not sold or bought any company stock. Plexus has received no research coverage in the past 90 days. Raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a lower news sentiment than the 0.48 average news sentiment score of Computer and Technology companies.

Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Bloomberg Daybreak Middle East Bloomberg Daybreak Middle East. Live from Dubai, connecting Asian markets to the European opens. The show will focus on global macro issues with a middle eastern context, provide expert analysis of major market moving stories and speak with the biggest newsmakers in the region.

The company’s average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating. Plexus Corp., together with its subsidiaries, provides electronic manufacturing services in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Plexus Corp. was founded in 1979 and is headquartered in Neenah, Wisconsin. The electronic manufacturing services company posted revenue of $1.07 billion in the period, also exceeding Street forecasts. Intraday Data provided by FACTSET and subject to terms of use.

The technique has proven to be very useful for finding positive surprises. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Pliant Therapeutics is -7.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In the past three months, Pliant Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,210,030.00 in company stock.

Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies. Plexus came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.16 per share.

report

Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

This is a decrease of -67% compared to the previous 30 days. 11 people have searched for PLRX on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days. MarketBeat has tracked 14 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.

0 Comments

Leave a reply

Your email address will not be published.

*

©2024 Smoke Break Media

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account